Regimens* | Patients (N = 83) |
|---|
ABVD | 4 |
BEAM | 1 |
CHOP | 4 |
COP | 1 |
DHAP | 10 |
R-DHAP | 1 |
Endoxan | 1 |
ESHAP | 1 |
PAD | 1 |
R-EPOCH | 1 |
R-CHOP | 8 |
HyperCVAD | 8 |
Untreated | 42 |
- *ABVD—Doxorubicin hydrochloride (Adriamycin), Bleomycin sulfate, Vinblastine sulfate, and Dacarbazine; BEAM—Carmustine (BiCNU), Etoposide, Cytarabine (Ara-C, cytosine arabinoside), Melphalan; R-CHOP—Rituximab, Cyclophosphamide, Doxorubicin hydrochloride, Vincristine (Oncovin), Prednisolone; CTD—Cyclophosphamide (Endoxan), Thalidomide, Dexamethasone; DHAP—Dexamethasone, High-dose Ara-C, Platinol (cisplatin); ESHAP—Etoposide, Methylprednisolone, High-dose Ara-C, Cisplatin; PAD—Bortezomib, Doxorubicin, Dexamethasone; R-CD—Rituximab, Cyclophosphamide, Dexamethasone; P-CVP—Rituximab, Cyclophosphamide, Vincristine, Prednisolone; R-EPOCH—Rituximab, Etoposide, Prednisone, Vincristine, Cyclophosphamide, Doxorubicin; HyperCVAD—Cytarbine, Vincristine, Cyclophosphamide, Doxorubicine, Dexamethasone
Virology Journal